CWR22 Xenograft as an Ex Vivo Human Tumor Model for Prostate Cancer Gene Therapy

Abstract

Our findings suggest a broad application of this CWR22 xenograft primary culture system as an ex vivo tumor model for the evaluation and characterization of various candidate therapeutic genes for human prostate cancer gene therapy, including a cytokine gene-modified tumor vaccine strategy.